Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

Replacing fossil fuels with green hydrogen depends on creating demand by making it price competitive, as buyers are unwilling to pay "green premiums", Fortescue Energy CEO Mark Hutchinson told Reuters ...